Beckley Psytech receives FDA Investigational New Drug (IND) approval for Phase IIb study of BPL-003, a novel synthetic formulation of 5-MeO-DMT (Mebufotenin)
February 21, 2023Business Services
Oxford, United Kingdom – 21 FEBRUARY 2023 – Beckley Psytech Ltd, a private, clinical-stage biotechnology company dedicated to addressing neuropsychiatric …
Unum UK expands employee digital health app
February 21, 2023Medical Communications
Employee benefits provider Unum UK has expanded its available modules on its Help@hand app, which aims to provide digital health …
CSL receives CMA from the European Commission for haemophilia B drug
February 21, 2023Medical Communications
CSL, a biotech company, has announced that it has received conditional marketing authorisation (CMA) from the European Commission (EC) for …
Hemab secures $135m in Series B funding for rare bleeding disorder treatment
February 21, 2023Research and Development
Hemab Therapeutics announced it received $135m from their oversubscribed Series B funding round. The funding will be used for their …
Scancell shares encouraging results from phase 1/2 cancer trial
February 21, 2023Research and Development
Scancell Holdings PLC have shared early results from its phase 1/2 cancer study which appear “very encouraging”, according to one …
AstraZeneca and MSD present final results of key secondary overall survival endpoint from Phase III PROpel trial at ASCO GU Cancers Symposium
February 20, 2023Business Services
Results from the final prespecified overall survival (OS) analysis of the PROpel Phase III trial in metastatic castration-resistant prostate cancer …
SMC recommends Opdivo® (nivolumab) for use post-surgery in specific urothelial cancer patients
February 20, 2023Business Services
(Uxbridge, Middlesex, 13 February 2023) – The Scottish Medicines Consortium (SMC) has accepted Bristol Myers Squibb’s (BMS’) nivolumab for the …
Cabometyx® in combination with nivolumab shows durable survival benefits at over three-years’ follow-up in first-line advanced renal cell carcinoma
February 20, 2023Business Services
PARIS, FRANCE, STRICTLY EMBARGOED until 11.00pm CET, 13 February 2023 – Ipsen (Euronext: IPN; ADR: IPSEY) today announced three-year minimum, …
Janssen Presents Updated Data Demonstrating Improved Outcomes from the Use of Niraparib in Combination with Abiraterone Acetate Plus Prednisone as a First-Line Therapy in Patients with BRCA-Positive Metastatic CastrationResistant Prostate Cance
February 20, 2023Business Services
BEERSE, BELGIUM, 16 February 2023 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced updated results from the …
FDA approves Apellis’ geographic atrophy treatment
February 20, 2023Medical Communications
Apellis’ Syfovre (pegcetacoplan injection) is indicated for patients with geographic atrophy (GA) with or without subfoveal involvement, and has received …
Medtronic’s extravascular defibrillator receives CE mark
February 20, 2023Medical Communications
Medtronic has received CE mark for its extravascular defibrillator. The Aurora EV-ICD™ MRI SureScan™ and Epsila EV™ MRI SureScan™ defibrillation …
Pfizer’s Lyme disease vaccine study cut due to protocol violations
February 20, 2023Medical Communications
Valneva and Pfizer have seen their Lyme disease vaccine study cut down after some clinical trial sites were revealed to …
Stryker’s Q Guidance System received FDA clearance for cranial applications
February 20, 2023Sales and Marketing
Stryker, a medical technology company, has announced that its Q Guidance System with Cranial Guidance Software received 510(k) clearance from …
Sun Pharma recalls at least 34,000 bottles of generic drug
February 13, 2023Medical Communications
Mumbai-based pharma company, Sun Pharma, has announced that it is recalling over 34,000 bottles of a generic drug, Diltiazem Hydrochloride, …
REGENXBIO presents interim phase 2 data from drug developed on NAVXpress™ platform
February 13, 2023Manufacturing and Production
REGENXBIO, a clinical-stage biotech company, has announced positive phase 2 data for their drug RXG-314, which was developed by the …
Scancell shares “highly encouraging” results from phase 1 COVID-19 vaccine trial
February 13, 2023Research and Development
Scancell Holdings PLC has shared “highly encouraging” results from its phase 1 clinical trial of its COVID-19 vaccines, says chief …
Sorrento Therapeutics’ subsidiary Scilex Holding Company acquires rights to acute migraine treatment
February 13, 2023Sales and Marketing
Scilex Holding Company, a majority-owned subsidiary of Sorrento Therapeutics, has announced that it has acquired the rights to ELYXYBTM (celecoxib oral …
UK pharma packaging giant Origin celebrates its 60th anniversary
February 13, 2023Business Services
13th FEBRUARY 2023, HULL, UK: Leading UK pharmaceutical packaging and solutions provider, Origin, is celebrating its 60th anniversary. Origin …
CYDAR MEDICAL RAISES $11.5M (£9.3M) IN SERIES A FUNDING ROUND
February 13, 2023Business Services
CAMBRIDGE, UNITED KINGDOM, 13 FEBRUARY 2023 – Cydar Medical (“Cydar” or “the Company”) a global, cloud-based surgical software company, announces …
AstraZeneca moves manufacturing to Ireland due to Britain’s tax regime
February 10, 2023Medical Communications
Big pharma giant, AstraZeneca, has announced that its plans to open a new facility in northwest England have now changed, …
Latest content
Scots neonatal innovations target hearing loss and earlier care
Agentis Health Group acquires Clinical Pharmacist Solutions
